Mriglobal
Mriglobal, doing business as Midwest Research Institute, is a 501(c)(3) not-for-profit research organization that provides scientific research, testing, training, and product development services to federal and commercial clients. The company specializes in areas such as medical countermeasure development, biosafety testing, threat detection technologies, and specialized training programs. Mriglobal conducts over $110 million in annual research for federal agencies including the Department of Health and Human Services, Department of Defense, and Department of Homeland Security. Through federal contract and grant awards, Mriglobal delivers a wide range of capabilities including analytical testing, biorepository management, pharmaceutical manufacturing, and infectious disease research.
Mriglobal has received numerous prime federal contract awards for diverse projects across multiple agencies. For the Department of Health and Human Services, Mriglobal has provided services such as drug toxicity testing, stability studies of investigational drugs, and maintenance of chemopreventive agent repositories for the National Institutes of Health. The company has also supported the Centers for Disease Control and Prevention with bacterial panel production and laboratory response network services. For the Department of Defense, Mriglobal has conducted research on nerve agent detection in military working dogs and provided biocontainment systems. The company has also supported the Department of Homeland Security with test and evaluation services for chemical countermeasures. Many of Mriglobal's contract awards involve specialized scientific equipment, biocontainment units, and laboratory services. The company frequently serves as both a prime contractor and subcontractor, partnering with universities, other research institutes, and small businesses to deliver comprehensive research and development services.
In terms of federal grant awards, Mriglobal has received funding to enhance its biorepository and life sciences capabilities. A $5 million grant from the Department of Health and Human Services is supporting the expansion of Mriglobal's biorepository facility in North Kansas City, Missouri, to advance the management of biologics and biological samples for clinical studies. Another grant is funding the expansion of life sciences capabilities at Mriglobal's headquarters to support research for multiple NIH organizations. As a subrecipient, Mriglobal has contributed to university-led research projects on topics such as dexamethasone therapy for ocular injuries from vesicating agents, development of antidotes for toxic gases, and sequencing of tick-borne viral disease agents. These grant-funded projects leverage Mriglobal's expertise in areas like analytical testing, animal studies, and specialized laboratory services.
Mriglobal holds several significant federal contract IDVs that enable agencies to rapidly procure its services. A $146.3 million IDV from the National Institute of Allergy and Infectious Diseases supports pre-clinical evaluation of infectious disease countermeasures. Another $49.7 million IDV from the National Center for Advancing Translational Sciences covers chemistry, manufacturing, and controls services for drug substance development. Mriglobal also holds a $100 million IDV from the Office of the Assistant Secretary for Preparedness and Response for biological animal model and medical countermeasure development. The company's IDVs span a range of capabilities including safety evaluation studies, diagnostic pre-clinical services, and rapid response research support. These vehicles allow agencies like NIH, CDC, and BARDA to issue task orders for Mriglobal's specialized scientific and technical services on an as-needed basis to support critical public health and national security programs.
HKQHNFKNKL15 541715
Not listed 425 Dr Martin Luther King Jr Blvd, Kansas City, MO 64110, USA
7/24/01 1/3/26 Battelle Memorial Institute
Battelle Memorial Institute, doing business as Battelle, is the world's largest independent nonprofit research and development organization. With over 20,000 employees globally, Battelle provides innovative solutions in national security, health, energy, and education sectors. As a nonprofit organization and manufacturer of goods, Battelle frequently provides research, engineering, testing, manufacturing, and information technology services to U.S. federal government agencies through prime and subcontract awards. The organization leverages its extensive scientific resources and technical capabilities across multiple research fields to address complex challenges for government and commercial clients.
Through prime federal contract awards, Battelle has provided the government with a wide range of goods and services across domains like defense, homeland security, health, energy, and transportation. Notable examples include delivering armored vehicles and integrated military systems to the United States Special Operations Command, developing chemical screening and nonclinical study services for the National Institutes of Health, manufacturing aircraft components like the Modular Aerial Spray System for the Department of the Air Force, supporting environmental programs like dredged material testing for the Army Corps of Engineers, and delivering research services for the Defense Advanced Research Projects Agency. Many contracts involve hardware development, laboratory testing, and technical research across chemical, biological, and engineering fields. Battelle serves as both a prime and subcontractor, frequently partnering with specialized manufacturers and technical consultants. Awards span contract types like definitive contracts, purchase orders, and delivery orders issued against IDIQ vehicles like OASIS and GSA Schedules. Few set-asides are specified on these awards issued by the Departments of Defense, Energy, Homeland Security, Health and Human Services, and other major federal agencies and offices.
On the grant side, Battelle has been awarded cooperative agreements by the Department of Energy to support carbon capture and storage technology initiatives, as well as Environmental Protection Agency project grants focused on environmental monitoring and remediation of critical minerals at mining sites. The National Science Foundation has issued cooperative agreements enabling Battelle to operate the National Ecological Observatory Network continental research platform and lead global collaborative networks advancing ecological drought research. These awards provide funding through federal programs like the DOE's Fossil Energy Research and Development, EPA's Consolidated Research/Training/Fellowships, and NSF's Biological Sciences for Battelle to conduct research, field studies, operational maintenance, training, and international partnership activities. Battelle frequently collaborates with universities and other research institutions on these federally-funded studies, combining complementary capabilities to advance scientific knowledge and develop new technologies with potential societal impact.
Battelle holds several major indefinite-delivery indefinite-quantity (IDIQ) contracts providing a broad scope of research, development, testing, and technical support services. These include a $100 million contract for biological animal model and medical countermeasure development through the HHS Biomedical Advanced Research and Development Authority, a $149 million vehicle for manufacturing and nonclinical studies of neurological therapeutic biotechnology products under NIH, and a $100 million EPA contract for chemical screening, review, and evaluation. The Department of Homeland Security awarded Battelle a $95 million single-award IDIQ for research and developmental testing related to transportation security, while the Defense Advanced Research Projects Agency issued an OT IDV valued at $32 million for initiatives like the Foundational Security for Food Systems program. Through these IDIQs, federal agencies gain flexible access to Battelle's extensive scientific resources and technical capabilities across a multitude of research fields.
F125YU6SWK59 541715
Not listed 505 King Ave, Columbus, OH 43201, USA
12/6/01 11/12/25 Lovelace Biomedical And Environmental Research Institute, Inc.
Lovelace Biomedical and Environmental Research Institute, Inc. (LBERI), doing business as Inhalation Toxicology Research Institute, is a not-for-profit contract research organization that provides preclinical research services to support the development of treatments and cures for respiratory diseases. As a subsidiary of Lovelace Biomedical Research Institute, LBERI leverages over 70 years of expertise in inhalation toxicology, infectious disease modeling, medical countermeasure testing, and translational science.
Through prime and subcontract awards, LBERI performs preclinical efficacy testing of HIV therapeutics, models pharmacodynamics of gene targets related to pain disorders, evaluates medical countermeasures for COVID-19, provides infectious disease modeling services, and conducts research on opioid addiction and withdrawal treatments. Major federal customers include NIH, NIAID, NCATS, BARDA, and Leidos. LBERI has provided these R&D services via cost-plus-fixed-fee and firm-fixed-price delivery orders issued under IDIQ contracts, with no set aside designations.
LBERI also conducts biomedical research on a range of disease states through NIH research project grants. As a prime grantee, LBERI performs studies on neural circuitry and dopamine reward response related to substance abuse. As a subrecipient on NIH awards to universities, LBERI contributes expertise in lung disease modeling, translational science, and biodistribution assays to support research on lung cancer, chronic bronchitis, and nanoparticle inhalation exposure.
N1UBCLRAPNG6 541380
Not listed Not listed 2/28/02 3/14/24 IIT Research Institute
IIT Research Institute (IITRI) is a non-profit contract research organization and division of the Illinois Institute of Technology that specializes in preclinical drug development services for federal agencies. IITRI primarily supports the Department of Health and Human Services by conducting pharmacology, toxicology, safety, and efficacy evaluations of small molecule, biologic, and RNA therapeutic candidates across various disease areas to support Investigational New Drug (IND) applications. The organization leverages its expertise in non-GLP and GLP studies, analytical assay development, and process validation to advance promising therapies from discovery through clinical trials. IITRI has extensive experience providing these services to federal agencies through both prime contracts and subcontracts.
IITRI has been awarded numerous contracts from agencies such as the National Cancer Institute (NCI), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Neurological Disorders and Stroke (NINDS), and National Center for Advancing Translational Sciences (NCATS). These contracts have supported a wide range of preclinical research activities, including toxicology studies for cancer therapies, safety assessments of potential treatments for neurological disorders, and evaluation of vaccine candidates for infectious diseases. Notable projects include preclinical development of an RNA vaccine for prostate cancer prevention, non-clinical safety studies of compounds for conditions like neuropathic pain and acute cannabinoid overdose, and toxicology testing of COVID-19 related therapies. IITRI has also conducted subcontract work for other research institutions, performing specialized studies such as repeat dose toxicity evaluations of multivalent vaccines. The contracts awarded to IITRI are typically not associated with set-aside designations.
IITRI holds several significant indefinite delivery/indefinite quantity (IDIQ) contract vehicles with federal agencies. These include a $146.3 million single-award contract with NIAID for preclinical models of infectious diseases, a $48.6 million multiple-award contract with NCATS for safety evaluation and toxicology studies, and a $150 million multiple-award contract with NCI for the PREVENT Cancer Preclinical Drug Development Program. Additionally, IITRI has a $9.8 million single-award contract with NCI for preclinical toxicology of small molecule drugs and a $174.5 million single-award contract with NINDS for the Pharmacology and Toxicology for Therapeutics Program. These IDIQ vehicles enable federal agencies to efficiently access IITRI's comprehensive preclinical research capabilities on an as-needed basis, supporting critical drug development efforts across multiple therapeutic areas. Task orders under these IDVs have been awarded by various NIH institutes to conduct specific preclinical studies, ranging from toxicology assessments of cancer therapies to safety evaluations of neurological treatments.
DGBUFQYMKWB5 541715
Not listed 10 W 35th St #4, Chicago, IL 60616, USA
4/15/02 10/8/25